Samsung Biologics stock faces labor uncertainty after 6.2% pay offer
Published on 11/20/2026 at 02:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLabor Talks Remain Unresolved
- Management proposed paying the negotiated wage increase before a final labor agreement is signed.
- The union continues to seek higher base pay and plans partial strike action through November 27.
Samsung Biologics proposed an early 6.2% wage increase during renewed negotiations with its union on November 17, according to The Asia Business Daily. The proposal would apply the increase with December pay and retroactively to fixed wages and eligible allowances paid since March, but it would not by itself constitute a final wage agreement.
Wage Proposal Leaves Core Dispute Open
Samsung Biologics said the advance payment was intended to improve employees' compensation while negotiations remain unresolved. The company plans to continue bargaining separately over a comprehensive wage and collective agreement.
The union is seeking a 9.5% increase in base pay, an additional lump-sum payment and a performance-bonus arrangement linked to operating profit. Partial strike action focused on quality and logistics departments is scheduled to continue through November 27, keeping labor relations and operational continuity in focus for investors.
CDMO Scale Meets Global Competition
Samsung Biologics is a South Korean biopharmaceutical contract development and manufacturing organization serving drug developers. Its platform spans large-scale biologics production and newer modalities including antibody-drug conjugates and peptides. It competes with global CDMOs such as Lonza, WuXi Biologics and FUJIFILM Biotechnologies, with Samsung focused on scale while those peers bring broader geographic or modality exposure.
Samsung Biologics at a Glance
- Company: Samsung Biologics
- ISIN: KR7207940008
- Headquarters: Incheon, Republic of Korea
- Business: Biopharmaceutical contract development and manufacturing
- Latest development: Early wage increase proposal made on November 17, 2026
South Korean equities remain the relevant market setting for Samsung Biologics, alongside the KOSPI market environment.
